STOCK TITAN

Medtronic - MDT STOCK NEWS

Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.

Overview

Medtronic (MDT) is a global healthcare technology company renowned for its development and manufacture of innovative therapeutic medical devices. Operating across a broad spectrum of chronic and acute medical conditions, Medtronic delivers solutions that range from cardiac care to neuromodulation, spinal treatments, and diabetes management. Leveraging advanced technology in areas such as robotics, imaging, and artificial intelligence, the company is central in addressing some of the most challenging health problems of our time.

Core Business and Products

Medtronic’s operations are built on decades of experience in designing, manufacturing, and marketing a diverse portfolio of medical devices. Their offering includes therapeutic devices such as pacemakers, defibrillators, heart valves, and stents, as well as advanced surgical tools, spinal fixation devices, neurovascular products, and insulin pumps. Each product category is developed through a rigorous process that emphasizes quality, patient safety, and robust clinical evidence. The company’s products are engineered to meet the demanding needs of healthcare institutions and professionals in both domestic and international markets.

Technological Innovation

At the core of Medtronic’s success is its commitment to technological innovation. The company integrates advanced systems in medical robotics, data analytics, and state-of-the-art imaging to enhance procedural accuracy. For instance, its ecosystem that connects navigation, robotics, and data analytics exemplifies how integrated solutions can lead to more predictable outcomes in complex procedures. Medtronic has also embraced adaptive technology in neuromodulation, shown by its work in adaptive deep brain stimulation, which personalizes therapy based on real-time neural signals.

Global Market Position and Operational Excellence

Medtronic operates with a global mindset, reaching patients in more than 150 countries. With its operational headquarters in the United States and legal headquarters in Ireland, the company effectively navigates diverse regulatory landscapes to maintain compliance while delivering high-quality medical devices. Approximately half of its revenue comes from international markets, underscoring its significance as a major player in the global medtech industry.

Partnerships and Industry Collaborations

Strategic partnerships further strengthen Medtronic’s market position. Collaborations with leading companies, such as those in imaging technology, enhance its product capabilities and help integrate novel hardware, software, and data-driven insights into clinical practice. These collaborations not only improve procedural outcomes but also provide a competitive edge in a field that continuously demands innovative therapeutic solutions.

Commitment to Quality and Clinical Expertise

Medtronic’s approach is deeply rooted in a commitment to clinical excellence and rigorous research. Every device is developed in accordance with strict quality controls and regulatory standards to ensure patient safety and efficacy. This clinical rigor, combined with an insatiable curiosity and diverse expertise, defines the company’s continued success. It is this commitment that has enabled Medtronic to remain at the forefront of treating over 70 critical health conditions through a continuously evolving product pipeline.

Industry Impact and Relevance

For investors and healthcare professionals, Medtronic represents more than just a manufacturer of medical devices. It embodies the transformative power of innovation in medicine by consistently addressing unmet clinical needs and improving patient outcomes. The company’s comprehensive portfolio and its integration of breakthrough technologies have set a benchmark for safety, reliability, and clinical performance in the competitive medical technology landscape.

Summary

In summary, Medtronic’s strength lies in its global scale, technological prowess, and ability to integrate complex therapeutic solutions seamlessly into clinical workflows. Its dedication to alleviating pain, restoring health, and extending life makes it a foundational pillar in modern healthcare, continuously evolving to meet the dynamic needs of patients and physicians alike.

Rhea-AI Summary

Medtronic plc (NYSE: MDT) has commenced its pivotal trial for the PulseSelect™ Pulsed Field Ablation (PFA) System, aimed at treating atrial fibrillation (AF). The trial, known as PULSED AF, is the first global study with investigational device exemption approval, assessing safety and efficacy across up to 500 patients in the U.S., Canada, Europe, and Australia. PulseSelect employs a non-thermal approach to disrupt irregular heart rhythms, potentially reducing damage to surrounding tissues. Preliminary results from pilot studies showed promising efficacy with no procedural complications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
none
-
Rhea-AI Summary

Medtronic plc (NYSE:MDT) has released new findings from the REVERSE trial, demonstrating the long-term benefits of cardiac resynchronization therapy (CRT) for patients with mild heart failure. The study indicates that patients who stabilize with CRT have similar longevity to those who improve, with five-year mortality rates at 10% for improved/stabilized patients versus 21% for worsened cases. The trial involved 406 patients, revealing a 73% lower risk of dying for CRT patients who stabilized compared to those whose condition worsened. The results emphasize the need for redefining CRT response classifications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
none
-
Rhea-AI Summary

Medtronic plc (NYSE:MDT) reported Q3 fiscal 2021 results, showing revenue of $7.775 billion, a 0.8% increase as reported but a 1.0% decline organically. GAAP diluted EPS was $0.94, while non-GAAP diluted EPS fell 10% to $1.29. U.S. revenue decreased 2%, while non-U.S. developed markets increased 6% as reported. The Cardiac and Vascular Group saw a 4.0% decrease in revenue, and the Minimally Invasive Therapies Group experienced a 6.3% increase, partly due to COVID-19 related products. The firm refrained from providing formal financial guidance due to ongoing uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
Rhea-AI Summary

Medtronic (NYSE:MDT) announced FDA approval for expanded MRI labeling of its InterStim™ II and InterStim™ Micro sacral neuromodulation systems using SureScan™ MRI leads. This updated labeling enhances MRI scan parameters and reduces wait times, improving patient access. New features include increased B1+rms settings for MRI scans and reduced maximum duration scan wait times from 60 to 5 minutes. The SureScan technology eliminates impedance checks before MRI, streamlining patient care. Medtronic continues to innovate in SNM therapy, highlighting over 70 FDA approvals for its InterStim portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
-
Rhea-AI Summary

Medtronic plc (NYSE: MDT) announced its participation in several upcoming virtual investor conferences. Key details include:

  • SVB Leerink Global Healthcare Conference on February 24, 2021, at 9:20 AM EST, featuring Mike Weinstein.
  • Citi's Healthcare Services Conference on February 25, 2021, at 2:25 PM EST, with Brett Wall speaking.
  • Cowen Annual Healthcare Conference on March 2, 2021, at 12:50 PM EST, featuring Karen Parkhill.
  • Oppenheimer Healthcare Conference on March 16, 2021, at 1:10 PM EDT, with Sean Salmon.

Webcasts will be available on Medtronic's investor relations page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
conferences
-
Rhea-AI Summary

On February 17, 2021, Medtronic plc (NYSE:MDT) announced a global recall of its Valiant Navion thoracic stent graft system due to safety concerns. This decision followed reports of stent fractures and associated serious complications in patients from the Valiant Evo Global Clinical Trial. Notably, one patient death was reported, and seven out of 87 patients showed stent ring enlargement. Medtronic is conducting a thorough investigation and has urged physicians to cease use of the device while prioritizing patient safety.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
Rhea-AI Summary

Medtronic plc (NYSE:MDT) will report its third quarter financial results for fiscal year 2021 on February 23, 2021, at 5:45 a.m. CST. The report will include financial data for the quarter ending January 29, 2021. Medtronic will hold a video webcast to discuss these results at 7:00 a.m. CST, available on their investor relations website. Future earnings releases are also scheduled through fiscal year 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
-
Rhea-AI Summary

Medtronic (NYSE:MDT) announced that leading spine surgeons in the U.S. have successfully performed surgeries using its Mazor Robotic Guidance System with newly cleared navigated disc prep and Midas Rex™ drills. These minimally invasive procedures demonstrate improved precision and planning, enhancing patient outcomes. Surgeons report significant benefits, including faster recoveries and reduced pain for patients. The technology's versatility allows seamless integration into existing workflows, even amidst the challenges posed by the COVID-19 pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
none
-
Rhea-AI Summary

Medtronic plc (NYSE:MDT) released findings from a study comparing the Nellcor™ Bedside SpO2 Patient Monitoring System and Masimo Radical-7® Pulse CO-Oximeter. The study indicated that Nellcor delivered a statistically significant faster stable oxygen saturation reading in newborns, averaging 15 seconds, compared to 27 seconds for Masimo. Additionally, heart rate discrepancies revealed Masimo often reported false bradycardia, while Nellcor closely aligned with ECG readings. This enhanced accuracy could impact neonatal resuscitation outcomes, adhering to neonatal resuscitation guidelines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
none
Rhea-AI Summary

Medtronic has expanded its radial artery access portfolio by acquiring RIST Neurovascular. This portfolio includes the first catheter designed for neurointerventions via the radial artery, enhancing Medtronic's capabilities in treating brain aneurysms and other neurovascular conditions. The Rist 079 Radial Access Guide Catheter and Selective Catheter have received FDA 501(k) clearance. Medtronic has completed over 80 cases with positive feedback from physicians, aiming to further develop this portfolio. Although initial revenue contributions are expected to be low, the acquisition aligns with Medtronic's long-term financial objectives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none

FAQ

What is the current stock price of Medtronic (MDT)?

The current stock price of Medtronic (MDT) is $88.49 as of April 1, 2025.

What is the market cap of Medtronic (MDT)?

The market cap of Medtronic (MDT) is approximately 113.8B.

What is the core business of Medtronic?

Medtronic develops and manufactures therapeutic medical devices for chronic diseases, including cardiac devices, neuromodulation, spinal therapies, and diabetes management tools.

How does Medtronic generate revenue?

The company generates revenue through the direct sale of its innovative medical devices and systems to healthcare institutions and professionals across the globe.

What markets does Medtronic serve?

Medtronic serves a global market, with significant operations in the United States, Europe, and other international markets, reaching patients in over 150 countries.

How does Medtronic maintain its competitive edge?

Medtronic maintains its competitive advantage through continuous technological innovation, strategic partnerships, and a commitment to clinical excellence and regulatory compliance.

What role do partnerships play in Medtronic's strategy?

Strategic partnerships, such as those with leading imaging and technology companies, enable Medtronic to integrate advanced features into its devices, thereby enhancing clinical outcomes and broadening its market reach.

How is Medtronic positioned in the medical technology industry?

Medtronic is a key player in the medtech industry, known for its comprehensive product portfolio, innovative technological solutions, and strong global market presence, addressing over 70 health conditions.

What types of products does Medtronic offer?

Medtronic offers a wide range of products including cardiac devices, spinal fixation systems, neurovascular products, insulin pumps, surgical tools, and advanced neuromodulation devices.

What distinguishes Medtronic's approach to innovation?

The company emphasizes rigorous clinical research, quality assurance, and the integration of cutting-edge technologies such as robotics and adaptive deep brain stimulation to deliver patient-centric solutions.

How does Medtronic address patient safety?

Medtronic adheres to strict quality controls and regulatory standards to ensure its devices are safe and effective, placing a high priority on patient outcomes and clinical performance.

What is Medtronic's global impact on healthcare?

By delivering innovative medical solutions and continuously evolving its product pipeline, Medtronic plays a critical role in transforming healthcare globally, positively impacting millions of patients every day.
Medtronic

NYSE:MDT

MDT Rankings

MDT Stock Data

113.81B
1.28B
0.26%
86.22%
1.05%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
Ireland
GALWAY